Arcus Biosciences (RCUS) Short-term Investments (2017 - 2026)
Arcus Biosciences (RCUS) posted quarterly Short-term Investments of $621.0 million for Q1 2026, down 22.86% year-over-year from $805.0 million in Q1 2025, and down 18.18% quarter-over-quarter from $759.0 million in Q4 2025.
Arcus Biosciences (RCUS) Short-term Investments (2017 - 2026) Analysis & Trends
Arcus Biosciences' Short-term Investments history runs 10 years deep, the most recent figure standing at $621.0 million for Q1 2026.
- In Q1 2026, Short-term Investments fell 22.86% year-over-year to $621.0 million; the TTM figure through Mar 2026 stood at $621.0 million (down 22.86% YoY), while the FY2025 annual figure was $759.0 million, down 8.33% from the prior year.
- Short-term Investments for Q1 2026 stood at $621.0 million, down from $759.0 million in the prior quarter.
- The five-year high for Short-term Investments was $900.1 million in Q2 2022, with the low at $593.0 million in Q3 2025.
- The 5-year median for Short-term Investments is $759.0 million (2025), against an average of $743.6 million.
- The sharpest annual moves came in 2022 and 2025: Short-term Investments surged 140.76% in 2022, then plunged 33.22% in 2025.
- Arcus Biosciences' Short-term Investments stood at $803.0 million in 2022, then retreated by 21.3% to $632.0 million in 2023, then surged by 31.01% to $828.0 million in 2024, then fell by 8.33% to $759.0 million in 2025, then dropped by 18.18% to $621.0 million in 2026.
- Business Quant data shows RCUS's Short-term Investments at $621.0 million in Q1 2026, $759.0 million in Q4 2025, and $593.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 552.00 Mn |
| Mar 31, 2026 | 621.00 Mn |
| Dec 31, 2025 | 759.00 Mn |
| Sep 30, 2025 | 593.00 Mn |
| Jun 30, 2025 | 663.00 Mn |
| Mar 31, 2025 | 805.00 Mn |
| Dec 31, 2024 | 828.00 Mn |
| Sep 30, 2024 | 888.00 Mn |
| Jun 30, 2024 | 813.00 Mn |
| Mar 31, 2024 | 810.00 Mn |
| Dec 31, 2023 | 632.00 Mn |
| Sep 30, 2023 | 615.00 Mn |
| Jun 30, 2023 | 700.00 Mn |
| Mar 31, 2023 | 716.00 Mn |
| Dec 31, 2022 | 803.00 Mn |
| Sep 30, 2022 | 831.14 Mn |
| Jun 30, 2022 | 900.15 Mn |
| Mar 31, 2022 | 664.75 Mn |
| Dec 31, 2021 | 351.00 Mn |
| Sep 30, 2021 | 345.21 Mn |